5.3 STEMI vs. NSTE-ACS Risk Stratification & Biomarkers

STEMI vs. NSTE-ACS Risk Stratification & Biomarkers

Once a patient with suspected Acute Coronary Syndrome (ACS) undergoes initial triage and a 12-lead ECG is obtained, the critical next step is to classify the type of ACS. This classification dictates the urgency and specific type of reperfusion therapy required. The primary tool for this immediate classification is the ECG, which broadly divides ACS into ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Segment Elevation ACS (NSTE-ACS).

Diagnosing STEMI

A STEMI typically indicates an acute, complete occlusion of a major epicardial coronary artery. This is a true medical emergency requiring immediate reperfusion therapy.

ECG Criteria for STEMI

The diagnosis of STEMI is primarily electrocardiographic. The hallmark finding is new ST-segment elevation at the J point in two or more contiguous leads. The specific voltage criteria vary slightly depending on the leads and the patient's demographics:

• General Criteria: ST-segment elevation of ≥ 1 mm (0.1 mV) in two contiguous leads (except V2-V3).
• Leads V2 and V3: Because normal individuals often have some ST elevation in these leads, the criteria are stricter:
  • Men ≥ 40 years: ≥ 2.0 mm (0.2 mV)
  • Men < 40 years: ≥ 2.5 mm (0.25 mV)
  • Women (all ages): ≥ 1.5 mm (0.15 mV)
• Contiguous Leads: Leads that look at the same anatomical region of the heart (e.g., II, III, aVF for the inferior wall; V1-V4 for the anterior wall; I, aVL, V5, V6 for the lateral wall).
• New LBBB: A new or presumably new Left Bundle Branch Block (LBBB) in the presence of ischemic symptoms is often treated as a STEMI equivalent, as the LBBB pattern can obscure the typical ST-segment changes.

Classifying NSTE-ACS

If the initial ECG does not show diagnostic ST-segment elevation (and no new LBBB is present), the patient is categorized as having NSTE-ACS. The ECG in NSTE-ACS may be completely normal, or it may show abnormalities such as ST-segment depression or T-wave inversion. The NSTE-ACS category is further subdivided based on the results of cardiac biomarkers.

Unstable Angina (UA) vs. NSTEMI

• Unstable Angina (UA): The patient experiences ischemic symptoms, but there is no evidence of myocardial necrosis (cardiac biomarkers remain normal). UA is primarily a clinical diagnosis based on the history of new-onset, worsening, or rest angina.
• Non-ST-Segment Elevation Myocardial Infarction (NSTEMI): The patient experiences ischemic symptoms, and there is evidence of myocardial necrosis, indicated by elevated cardiac biomarkers (specifically troponin).

The key distinction between UA and NSTEMI is the presence or absence of myocardial injury as detected by blood tests.

Cardiac Biomarkers: The Role of Troponin

Cardiac troponins (Troponin T and Troponin I) are regulatory proteins found in cardiac muscle. When myocardial cells are injured or die, these proteins are released into the bloodstream.

High-Sensitivity Cardiac Troponin (hs-cTn)

High-sensitivity cardiac troponin assays are now the preferred standard for diagnosing acute myocardial infarction. They can detect much lower concentrations of troponin than conventional assays, allowing for earlier detection of myocardial injury.

• Kinetics: With hs-cTn, elevations can often be detected within 1 to 3 hours after the onset of ischemia. Troponin levels typically peak within 12-24 hours and may remain elevated for several days to a week or more.
• Serial Testing: Because a single normal troponin value early in the course of symptoms does not rule out an MI, serial testing (e.g., at baseline and 1-3 hours later) is usually required to document a rising or falling pattern indicative of acute injury.
• Clinical Context: It is important to note that troponin is a marker of myocardial injury, not specifically ischemia. Conditions other than ACS can cause troponin elevation, including pulmonary embolism, heart failure, sepsis, and renal failure. The diagnosis of NSTEMI requires a characteristic rise and/or fall of troponin in the appropriate clinical context of suspected ischemia.

Risk Stratification Tools

For patients diagnosed with NSTE-ACS, the risk of adverse events (like death or progression to a full STEMI) varies significantly. Risk stratification tools are essential to identify high-risk patients who would benefit from an early invasive strategy (cardiac catheterization) versus a conservative, ischemia-guided strategy.

Common Scoring Systems

1. TIMI (Thrombolysis in Myocardial Infarction) Risk Score: A widely used, 7-point score that assesses variables such as age ≥ 65, presence of CAD risk factors, prior stenosis, aspirin use, severe angina, ST deviation, and positive cardiac markers. A higher score indicates a higher risk of adverse outcomes.
2. GRACE (Global Registry of Acute Coronary Events) Risk Model: A more complex tool that utilizes variables including age, heart rate, systolic blood pressure, creatinine level, Killip class, cardiac arrest at admission, ST-segment deviation, and elevated cardiac markers. It provides a more precise estimate of mortality risk at 6 months.

These objective tools help clinicians make evidence-based decisions regarding the timing and necessity of invasive procedures for patients with NSTE-ACS.